Where Do JAK inhibitors Fit in the Emerging Treatment
Paradigm in the Management of RA

New Horizons in the Treatment and Management of Rheumatoid Arthritis is a 4-part series
that will provide attendees with the latest information in RA Management

This is Part II of the series focusing on Where Do JAK inhibitors Fit in the
Emerging Treatment Paradigm in the Management of RA


This activity is an archive from the webinar held on February 3, 2017. If you participated in the
February 3 webinar, you are not eligible to receive credits from this activity. 

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is valid from April 1, 2017 to April 30, 2019
 

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Lilly, USA LLC

Description:
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.

Upon Completion of this activity, participants will be able to:

  • Review efficacy and safety data and updates of new and emerging JAK inhibitors in the management of RA for achieving treatment goals

  • Examine the place in therapy for JAK inhibitors based on established RA guidelines, available clinical data and ongoing clinical trials

  • Implement tailored treatment regimens for moderate-to-severely active RA based on repeated assessment of disease activity, functional status, treatment response, and other patient-specific risks

  • Discuss recent clinical trial data of emerging JAK inhibitors in patients with rheumatoid arthritis
     

Faculty: Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic, Lerner College of Medicine
Director
R J Fasenmyer Center for Clinical Immunology

Disclosure:

Dr. Calabrese serves as a consultant to AbbVie, Crescendo, GlaxoSmithKline, Janssen, Pfizer, Regeneron, and UCB. He also serves on the speaker’s bureau for AbbVie, Bristol-Myers Squibb, Genentech, Janssen, and UCB. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Lilly, USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue